FindTrial
Sign In

MT-3724

DRUG4 trials

Sponsors

Molecular Templates, Inc.

Conditions

Chronic B-cell Lymphocytic LeukemiaNon-Hodgkin's B-cell LymphomaNon-hodgkin LymphomaNon-hodgkin Lymphoma,B CellRefractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B-Cell LymphomaSmall Lymphocytic Leukemia

Phase 1

Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
WithdrawnNCT02556346
Molecular Templates, Inc.Chronic B-cell Lymphocytic Leukemia, Small Lymphocytic Leukemia
Start: 2015-11-30End: 2016-12-31Updated: 2016-03-02

Phase 2

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
TerminatedNCT03488251
Molecular Templates, Inc.Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Start: 2018-08-20End: 2021-03-12Updated: 2022-08-16
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)
TerminatedNCT03645395
Molecular Templates, Inc.Non-hodgkin Lymphoma
Start: 2019-04-08End: 2021-03-10Updated: 2022-08-16

Unknown Phase

Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
NCT02715843
Molecular Templates, Inc.Non-Hodgkin's B-cell Lymphoma
Updated: 2019-10-11

Related Papers

Abstract PO-63: A phase 2a open-label study of MT-3724, a novel CD20-targeting engineered toxin body, in combination with lenalidomide (LEN) in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL)
Blood Cancer Discovery2020-11-013 citations
Antibodies to watch in 2020.
2020-01-01328 citations
A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Blood2019-11-133 citations
A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Blood2019-11-132 citations
Abstract 2060: Combination of CD20 targeted engineered toxin body, MT-3724, with chemotherapy or IMiDs for the treatment of non Hodgkin's lymphoma
Cancer Research2019-07-012 citations
Abstract 2060: Combination of CD20 targeted engineered toxin body, MT-3724, with chemotherapy or IMiDs for the treatment of non Hodgkin's lymphoma
Experimental and Molecular Therapeutics2019-07-011 citations